nodes	percent_of_prediction	percent_of_DWPC	metapath
Nebivolol—Allergic cutaneous angiitis—Sorafenib—liver cancer	0.115	0.115	CcSEcCtD
Nebivolol—Leukocytoclastic vasculitis—Sorafenib—liver cancer	0.0747	0.0747	CcSEcCtD
Nebivolol—Renal failure acute—Sorafenib—liver cancer	0.0288	0.0288	CcSEcCtD
Nebivolol—Aspartate aminotransferase increased—Sorafenib—liver cancer	0.0239	0.0239	CcSEcCtD
Nebivolol—Psoriasis—Epirubicin—liver cancer	0.0215	0.0215	CcSEcCtD
Nebivolol—Erectile dysfunction—Sorafenib—liver cancer	0.0212	0.0212	CcSEcCtD
Nebivolol—Acute coronary syndrome—Sorafenib—liver cancer	0.0202	0.0202	CcSEcCtD
Nebivolol—Myocardial infarction—Sorafenib—liver cancer	0.0201	0.0201	CcSEcCtD
Nebivolol—Psoriasis—Doxorubicin—liver cancer	0.0199	0.0199	CcSEcCtD
Nebivolol—Cardiac disorder—Sorafenib—liver cancer	0.0171	0.0171	CcSEcCtD
Nebivolol—Mental disorder—Sorafenib—liver cancer	0.0161	0.0161	CcSEcCtD
Nebivolol—Malnutrition—Sorafenib—liver cancer	0.016	0.016	CcSEcCtD
Nebivolol—Angioedema—Sorafenib—liver cancer	0.0146	0.0146	CcSEcCtD
Nebivolol—Syncope—Sorafenib—liver cancer	0.0144	0.0144	CcSEcCtD
Nebivolol—Loss of consciousness—Sorafenib—liver cancer	0.0141	0.0141	CcSEcCtD
Nebivolol—Atrioventricular block—Epirubicin—liver cancer	0.014	0.014	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.0135	0.0135	CcSEcCtD
Nebivolol—Atrioventricular block—Doxorubicin—liver cancer	0.0129	0.0129	CcSEcCtD
Nebivolol—Shock—Sorafenib—liver cancer	0.0129	0.0129	CcSEcCtD
Nebivolol—Nervous system disorder—Sorafenib—liver cancer	0.0128	0.0128	CcSEcCtD
Nebivolol—Thrombocytopenia—Sorafenib—liver cancer	0.0128	0.0128	CcSEcCtD
Nebivolol—Skin disorder—Sorafenib—liver cancer	0.0127	0.0127	CcSEcCtD
Nebivolol—Dyspnoea—Sorafenib—liver cancer	0.0117	0.0117	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Sorafenib—liver cancer	0.0113	0.0113	CcSEcCtD
Nebivolol—Fatigue—Sorafenib—liver cancer	0.0113	0.0113	CcSEcCtD
Nebivolol—Gastrointestinal pain—Sorafenib—liver cancer	0.0107	0.0107	CcSEcCtD
Nebivolol—Renal failure acute—Epirubicin—liver cancer	0.0106	0.0106	CcSEcCtD
Nebivolol—Urticaria—Sorafenib—liver cancer	0.0104	0.0104	CcSEcCtD
Nebivolol—Abdominal pain—Sorafenib—liver cancer	0.0103	0.0103	CcSEcCtD
Nebivolol—Renal failure acute—Doxorubicin—liver cancer	0.00985	0.00985	CcSEcCtD
Nebivolol—Hypersensitivity—Sorafenib—liver cancer	0.00963	0.00963	CcSEcCtD
Nebivolol—Asthenia—Sorafenib—liver cancer	0.00938	0.00938	CcSEcCtD
Nebivolol—Pruritus—Sorafenib—liver cancer	0.00925	0.00925	CcSEcCtD
Nebivolol—Diarrhoea—Sorafenib—liver cancer	0.00894	0.00894	CcSEcCtD
Nebivolol—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.00885	0.00885	CcSEcCtD
Nebivolol—Dizziness—Sorafenib—liver cancer	0.00864	0.00864	CcSEcCtD
Nebivolol—Vomiting—Sorafenib—liver cancer	0.00831	0.00831	CcSEcCtD
Nebivolol—Rash—Sorafenib—liver cancer	0.00824	0.00824	CcSEcCtD
Nebivolol—Dermatitis—Sorafenib—liver cancer	0.00823	0.00823	CcSEcCtD
Nebivolol—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.00819	0.00819	CcSEcCtD
Nebivolol—Headache—Sorafenib—liver cancer	0.00819	0.00819	CcSEcCtD
Nebivolol—Nausea—Sorafenib—liver cancer	0.00776	0.00776	CcSEcCtD
Nebivolol—Bradycardia—Epirubicin—liver cancer	0.00692	0.00692	CcSEcCtD
Nebivolol—Oedema peripheral—Epirubicin—liver cancer	0.0067	0.0067	CcSEcCtD
Nebivolol—Bradycardia—Doxorubicin—liver cancer	0.0064	0.0064	CcSEcCtD
Nebivolol—Cardiac disorder—Epirubicin—liver cancer	0.00631	0.00631	CcSEcCtD
Nebivolol—Oedema peripheral—Doxorubicin—liver cancer	0.0062	0.0062	CcSEcCtD
Nebivolol—Mental disorder—Epirubicin—liver cancer	0.00596	0.00596	CcSEcCtD
Nebivolol—Malnutrition—Epirubicin—liver cancer	0.00592	0.00592	CcSEcCtD
Nebivolol—Cardiac disorder—Doxorubicin—liver cancer	0.00584	0.00584	CcSEcCtD
Nebivolol—Mental disorder—Doxorubicin—liver cancer	0.00551	0.00551	CcSEcCtD
Nebivolol—Malnutrition—Doxorubicin—liver cancer	0.00548	0.00548	CcSEcCtD
Nebivolol—Vertigo—Epirubicin—liver cancer	0.00532	0.00532	CcSEcCtD
Nebivolol—Syncope—Epirubicin—liver cancer	0.00531	0.00531	CcSEcCtD
Nebivolol—Loss of consciousness—Epirubicin—liver cancer	0.0052	0.0052	CcSEcCtD
Nebivolol—Chest pain—Epirubicin—liver cancer	0.00504	0.00504	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.005	0.005	CcSEcCtD
Nebivolol—Vertigo—Doxorubicin—liver cancer	0.00492	0.00492	CcSEcCtD
Nebivolol—Syncope—Doxorubicin—liver cancer	0.00491	0.00491	CcSEcCtD
Nebivolol—Loss of consciousness—Doxorubicin—liver cancer	0.00481	0.00481	CcSEcCtD
Nebivolol—Shock—Epirubicin—liver cancer	0.00475	0.00475	CcSEcCtD
Nebivolol—Nervous system disorder—Epirubicin—liver cancer	0.00474	0.00474	CcSEcCtD
Nebivolol—Thrombocytopenia—Epirubicin—liver cancer	0.00473	0.00473	CcSEcCtD
Nebivolol—Skin disorder—Epirubicin—liver cancer	0.00469	0.00469	CcSEcCtD
Nebivolol—Chest pain—Doxorubicin—liver cancer	0.00466	0.00466	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00463	0.00463	CcSEcCtD
Nebivolol—Shock—Doxorubicin—liver cancer	0.0044	0.0044	CcSEcCtD
Nebivolol—Nervous system disorder—Doxorubicin—liver cancer	0.00438	0.00438	CcSEcCtD
Nebivolol—Thrombocytopenia—Doxorubicin—liver cancer	0.00438	0.00438	CcSEcCtD
Nebivolol—Insomnia—Epirubicin—liver cancer	0.00437	0.00437	CcSEcCtD
Nebivolol—Skin disorder—Doxorubicin—liver cancer	0.00434	0.00434	CcSEcCtD
Nebivolol—Paraesthesia—Epirubicin—liver cancer	0.00434	0.00434	CcSEcCtD
Nebivolol—Dyspnoea—Epirubicin—liver cancer	0.00431	0.00431	CcSEcCtD
Nebivolol—Somnolence—Epirubicin—liver cancer	0.00429	0.00429	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Epirubicin—liver cancer	0.00417	0.00417	CcSEcCtD
Nebivolol—Fatigue—Epirubicin—liver cancer	0.00416	0.00416	CcSEcCtD
Nebivolol—Insomnia—Doxorubicin—liver cancer	0.00404	0.00404	CcSEcCtD
Nebivolol—Paraesthesia—Doxorubicin—liver cancer	0.00401	0.00401	CcSEcCtD
Nebivolol—Dyspnoea—Doxorubicin—liver cancer	0.00398	0.00398	CcSEcCtD
Nebivolol—Somnolence—Doxorubicin—liver cancer	0.00397	0.00397	CcSEcCtD
Nebivolol—Gastrointestinal pain—Epirubicin—liver cancer	0.00395	0.00395	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00386	0.00386	CcSEcCtD
Nebivolol—Fatigue—Doxorubicin—liver cancer	0.00385	0.00385	CcSEcCtD
Nebivolol—Urticaria—Epirubicin—liver cancer	0.00384	0.00384	CcSEcCtD
Nebivolol—Abdominal pain—Epirubicin—liver cancer	0.00382	0.00382	CcSEcCtD
Nebivolol—Gastrointestinal pain—Doxorubicin—liver cancer	0.00365	0.00365	CcSEcCtD
Nebivolol—Hypersensitivity—Epirubicin—liver cancer	0.00356	0.00356	CcSEcCtD
Nebivolol—Urticaria—Doxorubicin—liver cancer	0.00355	0.00355	CcSEcCtD
Nebivolol—Abdominal pain—Doxorubicin—liver cancer	0.00353	0.00353	CcSEcCtD
Nebivolol—Asthenia—Epirubicin—liver cancer	0.00347	0.00347	CcSEcCtD
Nebivolol—Pruritus—Epirubicin—liver cancer	0.00342	0.00342	CcSEcCtD
Nebivolol—Diarrhoea—Epirubicin—liver cancer	0.00331	0.00331	CcSEcCtD
Nebivolol—Hypersensitivity—Doxorubicin—liver cancer	0.00329	0.00329	CcSEcCtD
Nebivolol—Asthenia—Doxorubicin—liver cancer	0.00321	0.00321	CcSEcCtD
Nebivolol—Dizziness—Epirubicin—liver cancer	0.00319	0.00319	CcSEcCtD
Nebivolol—Pruritus—Doxorubicin—liver cancer	0.00316	0.00316	CcSEcCtD
Nebivolol—Vomiting—Epirubicin—liver cancer	0.00307	0.00307	CcSEcCtD
Nebivolol—Diarrhoea—Doxorubicin—liver cancer	0.00306	0.00306	CcSEcCtD
Nebivolol—Rash—Epirubicin—liver cancer	0.00305	0.00305	CcSEcCtD
Nebivolol—Dermatitis—Epirubicin—liver cancer	0.00304	0.00304	CcSEcCtD
Nebivolol—Headache—Epirubicin—liver cancer	0.00303	0.00303	CcSEcCtD
Nebivolol—Dizziness—Doxorubicin—liver cancer	0.00296	0.00296	CcSEcCtD
Nebivolol—Nausea—Epirubicin—liver cancer	0.00287	0.00287	CcSEcCtD
Nebivolol—Vomiting—Doxorubicin—liver cancer	0.00284	0.00284	CcSEcCtD
Nebivolol—Rash—Doxorubicin—liver cancer	0.00282	0.00282	CcSEcCtD
Nebivolol—Dermatitis—Doxorubicin—liver cancer	0.00282	0.00282	CcSEcCtD
Nebivolol—Headache—Doxorubicin—liver cancer	0.0028	0.0028	CcSEcCtD
Nebivolol—Nausea—Doxorubicin—liver cancer	0.00265	0.00265	CcSEcCtD
